about
Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogsExons 19 and 21 of epidermal growth factor receptor are highly conserved in squamous cell cancer of the head and neckEndometrial cancer: what is new in adjuvant and molecularly targeted therapy?Hypoxia-inducible factor-1 as a therapeutic target in endometrial cancer managementPromising novel therapies for the treatment of endometrial cancerPrognostic biomarkers in ovarian cancer.Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour modelApplication of Immunohistochemistry and Molecular Diagnostics to Clinically Relevant Problems in Endometrial Cancer Bojana Djordjevic, Shannon Westin, Russell R. BroaddusThe molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies.Systemic therapy for recurrent endometrial cancer: a review of North American trials.Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part II.Endometrial cancer: redefining the molecular-targeted approach.Menadione induces the formation of reactive oxygen species and depletion of GSH-mediated apoptosis and inhibits the FAK-mediated cell invasion.Parthenolide induces apoptosis by activating the mitochondrial and death receptor pathways and inhibits FAK-mediated cell invasion.Brefeldin a induces apoptosis by activating the mitochondrial and death receptor pathways and inhibits focal adhesion kinase-mediated cell invasion.Inhibition of the Rho/ROCK pathway enhances the efficacy of cisplatin through the blockage of hypoxia-inducible factor-1α in human ovarian cancer cells.EGFR- and AKT-mediated reduction in PTEN expression contributes to tyrphostin resistance and is reversed by mTOR inhibition in endometrial cancer cells.Expression profiling of 22 genes involved in the PI3K-AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations.
P2860
Q33603032-CDAE6990-94A3-423D-95EB-630F0B621C03Q33621754-16C724CD-1D50-418A-9C7F-C8633850E603Q33633962-08FFD5B8-50BF-40B7-9D97-0BE640A8C512Q33652379-B4ED6037-04A9-4CC1-A40B-6245CED37BE7Q33920661-8E4857B1-B52D-4D74-B43B-00F115D788C7Q34086636-9E171A81-7409-434A-BAFC-3803A41ABD46Q36667406-272A039A-135C-43AC-BFB2-CC6F1ACDC6B9Q36841899-365878E2-2013-4372-8448-939A1C9420EDQ37349623-C91FCCDF-FFD5-43B2-B328-262ABBC323F8Q37546032-FDD1A04F-822A-47C4-9FA8-03D6C16E6162Q37882456-6B7D4FEE-CA0B-4F88-A0B0-5DE519D676A6Q38454955-AA8D5716-4673-4FAA-90E0-17F521EE28D8Q38989894-80C1FDDF-ED64-4410-8DBF-02BFC28949AFQ39092065-E15C9A29-E662-4A26-BC49-94519C879F76Q39130477-1AAC23EC-00ED-44BF-A787-44ACC3C1852EQ39396280-D8DAE297-8E4D-4993-BB8D-7DEDD49F6FDBQ39467200-D0364AD2-F420-4368-AE99-7C5ADE11534CQ39898816-A121C051-B88D-4F7C-93E7-CF5BB99F754E
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Targeted therapies in gynecologic cancers.
@ast
Targeted therapies in gynecologic cancers.
@en
type
label
Targeted therapies in gynecologic cancers.
@ast
Targeted therapies in gynecologic cancers.
@en
prefLabel
Targeted therapies in gynecologic cancers.
@ast
Targeted therapies in gynecologic cancers.
@en
P2093
P1476
Targeted therapies in gynecologic cancers.
@en
P2093
Hye Sook Chon
John J Kavanagh
P304
P356
10.2174/156800906777441799
P577
2006-06-01T00:00:00Z